Home » Topics » BioWorld Science

BioWorld Science
RSS

Discovery of novel hybrid compounds as antitubercular agents

Jan. 12, 2022

Dysregulation of the tRNA synthetase modulator NOTCH1 behind T-ALL pathogenesis

Jan. 12, 2022

CD22 aberrant splicing confers resistance to therapy in B-ALL

Jan. 12, 2022

Mydecine completes model of new serotonin receptor for AI-driven drug discovery program

Jan. 11, 2022

DiNAQOR and CMRI enter research collaboration on cardiac specific AAV capsids

Jan. 11, 2022

Amarna and Redoxis receive grant to support ALPHAVAC project in neurodegenerative diseases

Jan. 11, 2022

BioNTech and Crescendo Biologics partner to develop immunotherapies for cancer and other diseases

Jan. 11, 2022

Targeting aggregated TDP-43 as new strategy for development of ALS and FTLD therapies

Jan. 11, 2022

Acadia and Stroke collaborate on novel RNA-based medicines for neurodevelopmental diseases

Jan. 11, 2022

HotSpot and Caris enter strategic partnership to advance HotSpot's portfolio

Jan. 11, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...